Skip to main content
. Author manuscript; available in PMC: 2019 Oct 17.
Published in final edited form as: Sci Transl Med. 2019 Apr 17;11(488):eaav0936. doi: 10.1126/scitranslmed.aav0936

Figure 6. Subclone analysis of serially biopsied human TNBCs reveals lack of subclone enrichment after AC.

Figure 6.

A. Serial biopsies from two TNBC patients were analyzed by WES. The tumors’ volumetric changes in response to four cycles of AC treatment are indicated. PDT, atezolizumab + Abraxane. PaCT, panitumumab + carboplatin + paclitaxel (Taxol).

B. Line plots of estimated cellular prevalence of mutation clusters modeled by PyClone are shown. Each line represents a mutation cluster, and the thickness of the line is proportional to the number of mutations within the cluster. The number of mutations comprising each cluster is shown in parentheses.

C. These plots display the prevalence of subclones throughout treatment. Subclonal architecture was reconstructed based on PyClone results.